Pulse Biosciences Presents Late-Breaking Data from nPulse™ Cardiac Catheter System First-In-Human Feasibility Study at the AF Symposium

Core Insights - Pulse Biosciences, Inc. has announced late-breaking clinical data from its nPulse Cardiac Catheter first-in-human feasibility study, showcasing the successful treatment of atrial fibrillation in 150 patients [1] - The study highlights rapid procedure times and minimal adverse effects associated with the use of the proprietary Nanosecond Pulsed Field Ablation technology [1] Company Overview - Pulse Biosciences, Inc. is focused on developing innovative medical technologies, specifically utilizing nanosecond PFA energy for cardiac treatments [1] - The company is publicly traded on Nasdaq under the ticker symbol PLSE [1] Clinical Study Details - The feasibility study involved 150 patients and demonstrated effective treatment outcomes for atrial fibrillation [1] - The results were presented at the 31st Annual event, indicating the significance of the findings in the medical community [1]